Skip to main content

Javid Moslehi Archives

Study identifies targeted therapy’s cardiac risks

Sep. 25, 2019—After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

Read more


AHA statement supports vascular cardio-oncology

Feb. 21, 2019—The American Heart Association (AHA) has issued a scientific statement calling for the integration of cardio-oncology and vascular medicine to provide cancer patients and cancer survivors with optimal cardiovascular care.

Read more


Immunotherapies linked to specific heart complications

Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.

Read more


Cancer immunotherapy drugs linked with more serious heart effects

Mar. 12, 2018—Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.

Read more


My Southern Health: The ABCDEs of caring for the heart during cancer treatment—and beyond

Feb. 28, 2017—People who have dealt with cancer may also need to take special care of their hearts. Here’s how.

Read more


Study details rare heart risk of certain cancer therapies

Nov. 3, 2016—Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of...

Read more


Emerging field of cardio-oncology seeks better tools

Oct. 27, 2016—Improved therapies have led to a spike in the number of people living with cancer, and today there are more than 15.5 million survivors in the United States. However, some of these therapies can cause toxicities to the heart, the vessels and the body’s metabolism.

Read more


Prostate cancer survivors’ risk of heart disease studied

Feb. 4, 2016—The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease’s slow progression.

Read more


Cancer therapies’ impact on heart, kidneys explored

Sep. 24, 2015—Vanderbilt is embarking on a multi-disciplinary approach to understand how promising cancer treatments, specifically certain kinase inhibitors, affect the heart and kidneys.

Read more


Program focuses on heart health of cancer patients

Oct. 2, 2014—The Vanderbilt Cardio-Oncology program has fostered a special collaborative relationship combining the expertise of cardiologists and oncologists to understand the effects of cancer therapy on the heart. This type of collaboration is now helping to define the cardiovascular health of more than 14 million cancer survivors in the United States.

Read more


Recent Stories from VUMC News and Communications Publications

Keeping pace: Nashville, once a mid-size city with a Southern small-town feel, is experiencing explosive growth.

Vanderbilt Medicine

Keeping pace: Nashville, once a mid-size city with a Southern small-town feel, is experiencing explosive growth.

VUMC campus

VUMC campus

Vanderbilt University School of Medicine entrance

Vanderbilt University School of Medicine entrance

Vanderbilt University Adult Hospital with helipad

Vanderbilt University Adult Hospital with helipad

more